Danisco US Inc.

Other

Genencor International, Inc.

Danisco A/s, Genencor Division

M Harunur Rashid

Fernando Valle

Robert Mark Caldwell

Walter Weyler

Eugenio Ferrari

Carole Harbison

Manoj N Kumar

Volker Schellenberger

Fiona A Harding

Timothy C Dodge

Judith A Fox

Martin Roberge

Manoj Kumar

The present invention provides cells that have been genetically manipulated to have an altered capacity to produce expressed proteins. In particular, the present invention relates to Gram-positive microorganisms, such asspecies having enhanced expression of a protein of interest, wherein one or more chromosomal genes have been inactivated, and preferably wherein one or more chromosomal genes have been deleted from thechromosome. In some further embodiments, one or more indigenous chromosomal regions have been deleted from a corresponding wild-typehost chromosome.

[object Object]

Described herein are multimeric oxidoreductase complexes which function in the enzymatic conversion of a carbon substrate. The complexes comprise a dehydrogenase subunit and a cytochrome C subunit. Also described are polynucleotides coding for the multimeric complexes and methods of use thereof.

Multimeric oxidoreductases

The present invention concerns multimeric oxidoreductase complexes which function in the enzymatic conversion of a carbon substrate, said complexes having a dehydrogenase subunit and a cytochrome C subunit. The invention further relates to polynucleotides coding for the multimeric complexes and methods of use thereof.

Described are multimeric oxidoreductase complexes which function in the enzymatic conversion of a carbon substrate. The complexes having a dehydrogenase subunit and a cytochrome C subunit. Also described are polynucleotides coding for the multimeric complexes and methods of use thereof.

The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy.

Tab molecules

TAB molecules

The present invention relates to engineering metabolic pathways in bacterial host cells which results in enhanced carbon flow for the production of ascorbic acid (ASA) intermediates. In particular, the invention relates to increasing the production of ASA intermediates in bacterial cells by enhancing the availability of gluconate resulting from the inactivation of endogenous gluconate transporter genes.

Growing community of inventors

Sunnyvale, CA, United States of America

M Harunur Rashid